61 results about "Asthma symptoms" patented technology

A composition and various formulations comprise preventative or therapeutic amounts of an epiandrosterone, analogue thereof or salt thereof, and / or a ubiquinone or salt thereof, and a pharmaceutically or veterinarily acceptable carrier or diluent. The composition and formulations are useful for treating bronchoconstriction, respiratory tract inflammation and allergies, asthma, and cancer. A method of treating diseases associated with low adenosine levels or adenosine depletion comprises administering folinic acid or a pharmaceutically acceptable salt hereof in a preventative or therapeutic amount, or an amount effective to treat adenosine depletion.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.

The invention provides a medicinal composition for treating infant asthma, which is a preparation prepared from the following raw materials in part by weight: 52.5 to 97.5 parts of ephedra herb, 58.45 to 108.55 parts of rhizoma belamcandae, 11.55 to 21.45 parts of manchurian wildginger, 52.5 to 97.5 parts of pepperweed seed, 58.45 to 108.55 parts of radix scutellariae, 58.45 to 108.55 parts of common coltsfoot flower, and 58.45 to 108.55 parts of tatarian aster root. The invention also provides a preparation method and use of the medicinal composition. The medicinal composition has the effects of relieving exterior syndrome and promoting expectoration, removing phlegm and curing asthma, mainly treats young child cough, sputum obstruction on throat, asthmatic and breath holding symptom, and the like, and is applied to infant asthma, capillary bronchitis, asthma, and the like. The medicinal composition for treating the infant asthma has the advantages of clinical revealing rate of 73.3 percent, clinical total effective rate of 96.6 percent, and obvious improvement on relieving asthma symptoms after treatment.

The invention relates to a medicine for treating asthma and particularly relates to a traditional Chinese medicine for treating asthma by taking the plant Chinese herbal medicines as raw materials. The medicine for treating the asthma is composed of the following raw herbal materials in parts by weight: 5-10 parts of fritillaria cirrhosa, 5-15 parts of Herba Rabdosiae, 10-20 parts of Astragalus membranaceus, 10-20 parts of Rhodiola rosea, 10-15 parts of Chinese yam, 5-10 parts of ginseng, 5-10 parts of lucid ganoderma, 15-30 parts of poria cocos, 10-20 parts of Rhizoma Pinellinae Praeparata, 5-10 parts of herba andrographitis, 10-20 parts of edible tulip, 25-40 parts of giant knot weed, 10-20 parts of gecko and 5-10 parts of cartialgenous. The medicine for treating the asthma is obtained according to the clinical experiments for many years, mainly has the effects of tonifying qi and essence, reinforcing the vital essence and strengthening the primordial qi, and also has the functions of increasing immunity, removing dampness to reduce phlegm, nourishing heart and moistening lung; and the pathogenesis of the asthma can be eliminated after the asthma symptom is cured, the asthma can be completely cured and the athletic ability of the patient can be recovered.

Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

A real-time system and method for personal air pollution exposure and inhaled dose management is described. A personal device (e.g., smartphone) determines personal exposure and inhaled dose metrics (e.g., daily accumulated dose), and compares daily histories of these metrics with personal health histories (e.g., self-reported daily asthma symptoms / inhaler use) to provide notifications when adverse health effects (e.g., asthma exacerbation) are likely to occur. The system notifications provide a personalized exposure / dose management tool by recommending behavioral changes to reduce exposure / dose (e.g., change time-location, time-physical activities, building operation). These behavioral changes are then used by the system to modify the real-time exposure and dose determined by the system.

The invention provides a medicinal composition for treating asthma and a preparation method thereof. The medicinal composition for treating the asthma is prepared by adopting the process that 1-3 parts of ginseng, 2-6 parts of radix achyranthis bidentatae, 5-10 parts of prepared rehmannia root, 5-10 parts of radix ophiopogonis, 3-6 parts of dogwood, 1-3 parts of fructus lycii, 1-3 parts of schisandra chinensis, 3-6 parts of rhizoma zingiberis, 5-10 parts of rhizoma anemarrhenae, 5-10 parts of fritillaria thun-bergli, 5-10 parts of arisaema cum bile, 3-6 parts of rhizoma pinelliae, 2-5 parts of pericarpium citri reticulatae, 1-3 parts of saccharina japonica, 10-13 parts of platycodon grandiflorum, 11-13 parts of impatiens balsamina, 1-3 parts of walnut, 1-3 parts of sea-tangle and 1-3 parts of undaria pinnatifida are subjected to extracting, concentrating, drying, crushing and pelletizing. The medicinal composition has the efficacy of quickly solving the asthma symptom and has the characteristics of scientific prescription, simple preparation method, low processing cost, obvious treatment effect and no toxic or side effects.

The invention discloses a novel application of phloroglucinol, namely an application of phloroglucinol in preparing medicaments for treating bronchial asthma or chronic cough. The new application provides a new treatment way for patients with bronchial asthma and chronic cough; the phloroglucinol is used for relieving or treating the bronchial asthma and chronic cough diseases and obviously improving the cough, expectoration and asthma symptoms of the patients, has the advantages of no toxic and side effects, good treatment effect and the like, and is easily accepted by the patients.

The invention provides a food therapy composition for rhinitis, trachitis or asthma. The food therapy composition is mainly prepared from the following raw materials: lily flower, magnolia flower, sweet apricot kernels, white nuts, coix seeds, cottonseed kernels, walnuts, black sesame seeds, lotus seeds, pine nuts, fructus xanthii, platycladi seeds, ginseng, Chinese caterpillar fungus and ganoderma lucidum. The food therapy composition is eaten or taken by hundreds of people, is proved to be capable of effectively preventing or alleviating symptoms of rhinitis, trachitis or asthma, and even has the effect of curing rhinitis, trachitis or asthma.

The invention provides a use of a slug protein in preparing medicines for treating asthma and belongs to the technical field of the medicines. In order to solve the problems of the existing medicines for treating asthma, the slug protein is combined with appropriate medical accessories in use. The invention provides a new use of the slug protein in preparing the medicines for treating the asthma. Designed for special asthma symptoms, the content of the extracted and purified slug protein is 92-99%, and then the slug protein of the purity is prepared into medicines in various forms; the medicines are clear in ingredients, good in consistency, controllable in quality, good in curative effect on asthma symptoms and convenient to use.

The invention provides a traditional Chinese medicine preparation applied to the Yongquan acupoint for preventing and treating repeated attack of cough and asthma of chronic pulmonary system diseases. The preparation is prepared from the following raw materials in parts by weight: 3-8 parts of semen lepidii, 5-13 parts of semen brassicae, 8-15 parts of ligusticum wallichii, 5-13 parts of fructus psoraleae, 5-12 parts of cinnamon, 7-13 parts of asarum, 1-10 parts of epimedium, 1-8 parts of cicada slough, 5-13 parts of earthworm, 5-12 parts of caulis spatholobi, 1-8 parts of borneol and 0.1-1 part of musk. The traditional Chinese medicine preparation can be manufactured into cataplasm, traditional Chinese medicine gel, plastics, plaster, patches and the like, is prepared from pure traditional Chinese medicinal materials, and has the advantages of proper combination, exact curative effect, convenience in use, high safety, no side effect and the like. The preparation is applied to the Yongquan acupoint to achieve the effects of stimulating meridians and collaterals and absorbing drugs, so that pulmonary system disease related symptoms of patients can be improved, qi and blood of human bodies can be regulated, the immunity of patients can be improved, and the living quality of patients can be improved. The preparation is an efficient traditional Chinese medicinal externally applied preparation for preventing and improving chronic cough and asthma symptoms.

The invention discloses a medicine composition for preventing and treating asthma, containing active components of 1 percent by weight of inactivated mycobacterium phlei F.U.36 and 1000-2000 percent by weight of salbutamol sulfate. The medicine composition is used for treating patients suffering from mild to moderate bronchial asthma and according with the 2006GINA diagnosis standard, measuring the lung function (FEV1%, PEF%) of the patients before and after treatment and the airway reactivity (PD20-FEV1), observing the symptoms of the patients and untoward effects of medicaments, and the like, and the difference of the FEV1% and the PEF% has no statistical significance as comparison before and after the treatment; the PD20-FEV1 after the treatment is obviously increased (p is smaller than 0.01) than that before the treatment; the provocation test negative conversion ratio is 88.9% (24 cases); and after the treatment, the symptoms of the patients are obviously relieved or disappear. Results show that the medicine composition can rapidly lower the airway reactivity and relieve the symptoms of asthma.

The invention discloses a budesonide nanocrystal, a preparation method and application in atomization inhalation administration. The preparation method of the budesonide nanocrystal comprises the following steps: (1) dissolving budesonide into ethanol, filtering with a 0.22 [mu]m micro-porous membrane to obtain solution 1 and pre-cooling the solution 1 to the temperature of 0-3 DEG C; (2) dissolving a dispersing agent or a stabilizing agent into water for injection, filtering with a 0.22 [mu]m micro-porous membrane to obtain solution 2 and pre-cooling the solution 2 to the temperature of 0-3 DEG C for later use; and (3) stirring at the temperature of (-15)-(-20) DEG C, adding the pre-cooled solution 1 into the pre-cooled solution 2, stirring for 3-5 min and collecting budesonide nanocrystals used for preparing budesonide nano-suspension for atomization inhalation. The budesonide nanocrystals can be better distributed on the surface of a bronchus or a lung and have the beneficial effects of rapidly taking effect and rapidly relieving an asthma symptom; the nano-suspension can be atomized by a vibration net-type atomizer, so that the drug use area is small, the atomization treatment time is short, and the drug utilization ratio is high; and therefore, the drug taking compliance of patients can be improved, and the side effects of drugs can be reduced.

The invention discloses an IL-5-targeted antibody, and a preparation method and application thereof. Specifically, the invention discloses a novel IL-5-targeted murine or chimeric monoclonal antibody.The invention also discloses a method for preparing the monoclonal antibody. The monoclonal antibody can be combined with an IL-5 antigen with high specificity, has high affinity, and can well alleviate a series of asthma symptoms caused by IL-5, thereby playing a role in treating asthma.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses medicinal powder for treating a cough and asthma. The medicinal powder for treating the cough and the asthma is prepared from the following raw materials in parts by weight: 15 to 30 parts of radix platycodi, 15 to 30 parts of herba schizonepetae, 15 to 30 parts of radix asteris, 15 to 30 parts of radix peucedani, 15 to 30 parts of radix stemonae, 15 to 30 parts of radix scutellariae, 15 to 30 parts of fructus schisandrae chinensis, 15 to 30 parts of semen armeniacae amarae, 15 to 30 parts of semen persicae, 15 to 20 parts of rhizoma anemarrhenae, 15 to 20 parts of bulbus fritillariae cirrhosae, 30 to 50 parts of fructus gleditsiae abnormalis, 8 to 12 parts of rhizoma zingiberis and 1 to 5 parts of borneolum syntheticum. The medicinal powder for treating the cough and the asthma has quite good curative effects on cough and asthma symptoms of bronchitis, bronchial asthma, pulmonary emphysema and the like, can be used for enhancing the self immunity and resistance of a human body, can be used for effectively controlling the state of an illness not to recrudesce, has no obvious toxic and side effects and untoward effects, and has better social benefit and economic benefit.

The invention relates to the technical field of medicines, and in particular relates to an application of gerbera piloselloides and a gerbera piloselloides extract in preparation of medicines for preventing and / or treating asthma. Research finds that the gerbera piloselloides and the gerbera piloselloides extract, especially a 60% ethanol extraction part of gerbera piloselloides, can play an anti-asthma role by inhibiting IgE generation in serum and inhibiting the levels of IL-8, IL-5, TNF-alpha and other inflammatory factors, and have obvious anti-asthma activity, which indicates that the 60%ethanol extraction part of gerbera piloselloides after elution and purification with 10% ethanol can be used as an anti-asthma effective active part of gerbera piloselloides. The gerbera piloselloides and the gerbera piloselloides extract can obviously improve asthma symptoms, can improve allergic reaction symptoms; moreover, and relieving the damage degree of lung tissues, and can be used to prepare medicines for preventing or treating asthma. In addition, the gerbera piloselloides is a natural Chinese herbal medicine, is safe and is free of toxic and side effects when being used, and has agood application prospect.

The invention provides a processed product of solanum photeinocarpum. The product is obtained through taking fresh and pure products or immersed and fresh-keeping products or dry products or fresh juice products or a mixture of the dry products and the fresh juice products of a plurality of plant part combinations of the solanum photeinocarpum as raw materials and processing. The plurality of plant part combinations of the solanum photeinocarpum comprise one or more of all combinations of roots, stems, leaves, flowers and fruits of the solanum photeinocarpum, preferably the combination of thestems, the leaves and the fruits of the solanum photeinocarpum, further preferably nearly mature fruits or mature fruits of the solanum photeinocarpum. The processed product of the solanum photeinocarpum, provided by the invention, can be used for preparing medicines or health-care products capable of improving the immunity and inhibiting tumor growth or preparing medicines for relieving lung cough and asthma symptoms, protecting liver injuries, protecting gastric mucosal injuries or inhibiting skin dampness toxin.

The present invention relates to a system for monitoring asthma symptoms of a subject (12), comprising a monitoring unit (14) configured to monitor at least one objective asthma symptom of the subject, an analysis unit (16) configured to determine an asthma status of the subject based on the at least one objective asthma symptom monitored by the monitoring unit, a test unit (18) configured to provide a test for collecting subjective asthma symptoms from the subject, if the at least one objective asthma symptom monitored by the monitoring unit (14) has changed in a manner that the change reveals a deterioration of the asthma status of the subject. Further the system comprises a calibration unit (24) configured to calibrate the at least one objective asthma symptom gathered from the subject with respect to a calibration test, wherein the calibration unit (24) is arranged to perform calibration at least once during an initial phase of use of the system (10).

The invention discloses a fructus-trichosanthis phlegm-resolving binds-disspitating cough-suppressing panting-calming instant granule. Fructus-trichosanthis and bulbus fritillariae thunbergii are employed as sovereign medicines, and fructus aurantii, radix platycodonis, pericarpium citri reticulatae, rhizoma pinelliae preparatum, poria, fried rhizoma atractylodis macrocephalae and raw radix glycyrrhizae are employed as auxiliary materials, and steps of extraction, concentration drying, preparation of a soft material, pelletization, drying, particle finishing, sterilization and packaging are performed, so that the instant granule is prepared. The instant granule has the efficacy of clearing heat and detoxifying, dispelling dampness and dissipating binds, moistening lung and resolving phlegm, is capable of effectively alleviating and eliminating asthma and various symptoms caused by asthma, also has substantial treatment effect on allergic bronchial asthma, asthmatic bronchitis and various asthma symptoms caused by other causes, is fast in effectiveness, short in treatment course and free of side effect, and has the effective rate of 100%.

The present invention relates to a composition for preventing or treating asthma, having, an active ingredient, a saturated or unsaturated fatty acid having 12 to 22 carbon atoms. The saturated or unsaturated fatty acid functions to inhibit or eliminate various asthma symptoms induced by ovalbumin. Specifically, the fatty acid inhibits the proliferation of leukocytes, neutrophils, lymphocytes and monocytes in BALF and serum, inhibits the proliferation of bronchial epithelial cells, reduces mucus in bronchioles, and reduces infiltration of inflammatory cells around bronchioles and blood vessels in a dose-dependent manner. Also, the fatty acid induces a decrease in the expression of IFN-γ, IL-12p40, IL-4, IL-5, IL-13 and TNF-α, which are Th2 cell-related cytokines. Therefore, the fatty acid overcomes the side effects of current asthma therapeutic agents, has an excellent therapeutic effect without having toxicity, and may advantageously be used as a composition for preventing, treating or alleviating asthma.

The invention belongs to the field of pharmaceutical compositions, and provides an antiasthmatic drug composition. The effective ingredients of the antiasthmatic drug composition are composed of, by mass, 5 parts of salbutamol sulfate, 1-5 parts of herba ephedra extract and 1-5 parts of semen armeniacae amarae extract. The invention further provides double-pulse controlled-release pellet capsules containing the antiasthmatic drug composition. The pharmaceutical composition combines traditional Chinese medicine with western medicine, can achieve synergistic interaction, decrease the dosage and reduce the toxic and side effects of salbutamol sulfate and generation of the drug resistance and not only can control the asthma symptoms, but also can treat root causes.

The invention discloses a traditional Chinese medicine composition for treating pediatric thermal asthma and a preparation method thereof. The composition is prepared from ten traditional Chinese medicines including herba ephedrae, semen armeniacae amarae, radix scutellariae, cortex lycii radicis, lumbricus, semen lepidii, fructus perillae, radix salviae miltiorrhizae, radix paeoniae rubra and agrimonia pilosa ledeb according to a certain weight ratio, and can be prepared into traditional Chinese medicine oral preparations such as granules, capsules, tablets, syrups and mixtures. The traditional Chinese medicine composition disclosed by the invention has the effects of ventilating the lung, removing phlegm, dispersing blood stasis and relieving asthma, is clinically used for treating pediatric thermal asthma caused by wind-heat common cold and intrinsic phlegm-blood stasis accumulation, and is remarkable in curative effect. The composition is used for treating acute attack of pediatricbronchial asthma, and achieves satisfactory effects in relieving cough and asthma symptoms of pediatric patients and reducing recurrence times. Meanwhile, the composition has the advantages of beinggood in taste, free of side effects, good in compliance and the like, and is an innovation in medicine for treating pediatric thermal asthma.

The invention discloses a medicine for treating asthma and kidney qi deficiency, an animal model and an establishing and using method. The medicine for treating asthma and kidney qi deficiency is prepared from 12g of prepared rehmannia roots, 12g of pulp of dogwood fruit, 12g of rhizoma dioscoreae, 12g of rhizoma alismatis, 12g of radix sophorae flavescentis, 12g of Japanese metaplexis pericarp, 12g of tree peony bark, 12g of poria cocos, 5g of schisandra chinensis, 8g of agilawood pieces, 15g of inula flowers, 15g of indigo naturalis and clam powder and 15g of raw radix astragalis. In the early period, a kidney qi deficiency and asthma symptom combined rat model is established, and it is observed that kidney tonifying and asthma relieving soup and glucocorticoid can correct Th1 / Th2 unbalance by adjusting expression of transcription factors. Specificity transcription factors, key cell factors and tiny RNA of a T cell subset serve as indexes, an internal mechanism of kidney qi deficiency asthma attacking and Treg / Th balance is proved, and a multi-target-point multi-layered network type regulatory mechanism possibly existing in traditional Chinese medicine for treating asthma is disclosed.

A real-time system and method for personal air pollution exposure and inhaled dose management is described. A personal device (e.g., smartphone) determines personal exposure and inhaled dose metrics (e.g., daily accumulated dose), and compares daily histories of these metrics with personal health histories (e.g., self-reported daily asthma symptoms / inhaler use) to provide notifications when adverse health effects (e.g., asthma exacerbation) are likely to occur. The system notifications provide a personalized exposure / dose management tool by recommending behavioral changes to reduce exposure / dose (e.g., change time-location, time-physical activities, building operation). These behavioral changes are then used by the system to modify the real-time exposure and dose determined by the system.

The invention relates to a method for building an allergen-specific immunotherapy asthma model and belongs to the biotechnology field. The method comprises the steps of firstly sensitizing, then carrying out large dose allergen immunotherapy and finally stimulating and producing asthma symptoms. The method provided by the invention can realize an allergen immunotherapy asthma model with the same effect with the traditional therapy model (sensitization-stimulation-allergen immunotherapy), and a research period for building the asthma model is shortened at the same time.

Disclosed in the present invention are an antibody targeting IL-5, a preparation method therefor and use thereof. In particular, disclosed in the present invention is a novel murine-derived or chimeric monoclonal antibody targeting IL-5. Also disclosed in the present invention is a method for preparing said monoclonal antibody. The monoclonal antibody of the present invention is capable of binding IL-5 antigen with high specificity, has high affinity and can well alleviate a series of asthma symptoms caused by IL-5, thereby achieving the effect of treating asthma.

Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.